Stock Analiz

Vyome Holdings, Inc HIND

Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026

$1.58Market cap $11M
Open the interactive analysis →

Vyome Holdings, Inc (HIND) is a healthcare company listed in the US with a market value of about $11M. In the twelve months to September 30, 2026 it had revenue of $153095 and net income of -$4M, a net margin of -2455.6%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.9, 5-year revenue growth of -51% a year, a 5-year average ROIC of -367%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.

About Vyome

Vyome is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $3M in 2019 to $319714 in 2025, a decline of about 32.2% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 63185811% over three years (dilution for shareholders). It spends 184% of revenue on research and development.

Score: 1.0 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.9
Forward P/E—
P/FCF—
P/S72.4
P/B1.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−99%

Growth and quality

Revenue growth (1 yr)-96.0%
Revenue growth (5 yrs, per year)-51.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-846.9%
ROIC (5-yr avg.)-366.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$153095$319714$8M$9M$11M$14M$11M$3M
Net income-$4M-$10M-$1M-$11M-$46M-$63M-$22M-$24M
Free cash flow———-$17M-$22M-$16M-$9M-$23M
EPS (diluted)$4.58$-4.86$-6001.39$-237181.75$-13511071.16$-35852104.98$-38935395.51$-35351090.15
Net margin-2455.6%-3209.7%-18.1%-131.2%-411.2%-464.3%-191.4%-721.6%
ROIC—-217.7%-111.3%-175.5%-1199.7%-129.2%-42.9%-72.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $8.83, 459% above the current price; targets range from $3.50 to $15.00; the consensus rating is “none”; expected EPS is $-0.65 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Vyome’s P/E ratio?

About 0.9, based on the last twelve months of diluted earnings per share.

Is Vyome stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Vyome pay a dividend?

Not currently.

Is Vyome a good stock to buy?

We do not give buy or sell advice. Vyome scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.